IBEX Technologies Inc. (IBXNF)
IBEX Technologies Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Montreal, QC, CA. The stock last traded at $1.00, down 6.54% on the session, giving a market capitalisation of $25.3M. On trailing twelve-month figures it carries a trailing P/E of 9.06, a net margin of 52.0%. Its beta of -0.04 implies it has historically moved less than the broad market.
Operating internationally, with key markets spanning Canada, the United States, Germany, and the United Kingdom, IBEX Technologies Inc. focuses on the development and sale of enzymes for various biomedical purposes. Its extensive product catalog includes a range of recombinant glycosaminoglycan lyases, such as Heparinase I, II, and III, alongside Chondroitinase AC and B. The company also provides sophisticated research tools, including collagen ELISAs designed to assess the formation and breakdown of connective tissue components, as well as collagen antibodies and a liquid diamine oxidase product. Furthermore, IBEX develops and commercializes various assays specifically tailored for research into osteoarthritis. Beyond its product lines, IBEX offers specialized services like lyophilization for creating disposable medical device parts, custom fermentation, and contract manufacturing. The firm caters to a broad clientele, encompassing medical device producers, quality control laboratories, manufacturers of low molecular weight heparin, and academic research institutions. IBEX Technologies Inc. was founded in 1972 and maintains its headquarters in Montreal, Canada.
IBEX Technologies Inc. is most often compared with the following Healthcare names: